Clinical Trial Update: A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients [Phase 2]

View source ↗

Summary

A Phase II trial evaluating the combination of docetaxel and carboplatin in chemonaive hormone-refractory prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Taxotere (docetaxel)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Hormone-Refractory Prostate Cancer | Phase 2 | Status: COMPLETED